Wednesday, 27. June 2012
Growing resistance of Plasmodium falciparum to existing drugs has led to the search for new antimalarial therapy. Tigecycline is a new class of antibiotics called glycylcycline presenting unique and innovative methods of action against bacteria and are specifically designed to overcome the two mechanisms of resistance to tetracycline. Clinical studies have demonstrated that tigecycline is easy to administer and is generally well tolerated with a twice daily regimen.Starzengruber, K. Thriemer, R. Haque, WA Khan, HP Fuhrer, A. Siedler, V. Hofecker, B. Ley, WH Wernsdorfer, H. Noedl. 2009. Antimalarials activities of tigecycline, a new antibiotic glycylcycline. Antimicrobial Agents and Chemotherapy, 53 9. 4040-4042).
We conclude that tigecycline has a significant antimalarial activity by itself and can be a potential candidate for the exploration of its clinical efficacy in combination with antimalarials act more quickly in the parenteral treatment of multidrug-resistant falciparum malaria among critically ill patients, say the researchers.
AGES is responsible for various tasks in the field of public health and food safety for the Austrian government.